D.E. Shaw & Co’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

D.E. Shaw & Co’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$52M	Sell	328,794 -1,038,998	-76%	-$140M	0.02%	739
2026 Q1	$175M	Buy	1,367,792 +630,015	+85%	+$78.6M	0.11%	220
2025 Q4	$90M	Buy	+737,777	New	+$84.6M	0.05%	440
2025 Q3	–	Sell	-62,064	Closed	-$5.15M	–	4975
2025 Q2	$5.15M	Sell	62,064 -181,427	-75%	-$14.5M	﹤0.01%	2014
2025 Q1	$19.7M	Sell	243,491 -129,936	-35%	-$11.6M	0.02%	953
2024 Q4	$33.6M	Sell	373,427 -629,378	-63%	-$61M	0.02%	747
2024 Q3	$99.1M	Buy	+1,002,805	New	+$98.5M	0.09%	272
2024 Q2	–	Sell	-303,111	Closed	-$28.8M	–	4883
2024 Q1	$28.8M	Buy	+303,111	New	+$28.1M	0.02%	714
2023 Q2	–	Sell	-1,103,000	Closed	-$84.1M	–	4609
2023 Q1	$84.1M	Sell	1,103,000 -183,200	-14%	-$15.2M	0.09%	262
2022 Q4	$107M	Buy	1,286,200 +771,200	+150%	+$62.4M	0.12%	187
2022 Q3	$40.9M	Buy	+515,000	New	+$43.4M	0.05%	479
2021 Q2	–	Sell	-14,700	Closed	-$1.99M	–	5054
2021 Q1	$1.99M	Buy	+14,700	New	+$2.2M	﹤0.01%	2590
2020 Q2	–	Sell	-18,690	Closed	-$1.45M	–	4285
2020 Q1	$1.45M	Sell	18,690 -25,000	-57%	-$2.21M	﹤0.01%	2437
2019 Q4	$4.16M	Hold	43,690	–	–	﹤0.01%	1869
2019 Q3	$3.33M	Buy	+43,690	New	+$3.63M	﹤0.01%	1964
2017 Q1	–	Sell	-10,000	Closed	-$592K	–	3642
2016 Q4	$592K	Buy	+10,000	New	+$617K	﹤0.01%	2753
2016 Q3	–	Sell	-47,700	Closed	-$2.58M	–	3576
2016 Q2	$2.58M	Buy	+47,700	New	+$2.61M	﹤0.01%	1742

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

D.E. Shaw & Co's XBI Position: Q2 2026 in Review

D.E. Shaw & Co reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 76% in Q2 2026, selling an estimated $140M and leaving 328,794 shares worth $52M. The position accounts for 0.02% of the portfolio, ranked #739.

D.E. Shaw & Co first reported a position in XBI in Q2 2016 and has held it in 17 quarters since. The position peaked at $175M in Q1 2026. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

D.E. Shaw & Co held 328,794 shares of State Street SPDR S&P Biotech ETF worth $52M as of Q2 2026.
D.E. Shaw & Co sold 1,038,998 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $140M.
State Street SPDR S&P Biotech ETF made up 0.02% of D.E. Shaw & Co's portfolio in Q2 2026, its #739 holding.
D.E. Shaw & Co first reported a position in State Street SPDR S&P Biotech ETF in Q2 2016 and has held it in 17 quarters since.
D.E. Shaw & Co's State Street SPDR S&P Biotech ETF position peaked at $175M in Q1 2026.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.